within Pharmacolibrary.Drugs.ATC.A;

model A10BX03
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.72,
    Cl             = 3e-05,
    adminDuration  = 600,
    adminMass      = 120 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.009300000000000001,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.035,
    Tlag           = 600,            
    Vdp             = 0.0162,
    k12             = 4.3,
    k21             = 4.3
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A10BX03</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Nateglinide is a rapid-acting oral hypoglycemic agent belonging to the meglitinide class used in the treatment of type 2 diabetes mellitus. It stimulates insulin release from pancreatic beta cells and is approved for glycemic control used today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult subjects after a single oral dose.</p><h4>References</h4><ol><li><p>Halas, CJ (2001). Nateglinide. <i>American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists</i> 58(13) 1200–1205. DOI:<a href=&quot;https://doi.org/10.1093/ajhp/58.13.1200&quot;>10.1093/ajhp/58.13.1200</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11449877/&quot;>https://pubmed.ncbi.nlm.nih.gov/11449877</a></p></li><li><p>Dunn, CJ, &amp; Faulds, D (2000). Nateglinide. <i>Drugs</i> 60(3) 607–617. DOI:<a href=&quot;https://doi.org/10.2165/00003495-200060030-00007&quot;>10.2165/00003495-200060030-00007</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/11030470/&quot;>https://pubmed.ncbi.nlm.nih.gov/11030470</a></p></li><li><p>Sunkara, G, et al., &amp; Ligueros-Saylan, M (2004). The effect of nateglinide on the pharmacokinetics and pharmacodynamics of acenocoumarol. <i>Current medical research and opinion</i> 20(1) 41–48. DOI:<a href=&quot;https://doi.org/10.1185/030079903125002685&quot;>10.1185/030079903125002685</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/14741071/&quot;>https://pubmed.ncbi.nlm.nih.gov/14741071</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A10BX03;
